M. Dalakas, G. Rakocevic, M. Salajegheh, J. Dambrosia, A. Hahn et al., Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology, vol.358, issue.5 pt 1, pp.286-293, 2009.
DOI : 10.1002/ana.21577

R. Graham and R. Hughes, A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.973-976, 2006.
DOI : 10.1136/jnnp.2005.081547

I. Merkies, P. Schmitz, F. Van-de-meche, and P. Van-doorn, Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies, Neurology, vol.54, issue.4, pp.943-949, 2002.
DOI : 10.1212/WNL.54.4.943

E. Delmont, C. Benaïm, M. Launay, S. Sacconi, M. Soriani et al., Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?, Journal of Neurology, vol.118, issue.1, pp.256-1876, 2009.
DOI : 10.1007/s00415-009-5217-0

N. Latov and S. Renaud, Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies, Journal of the Neurological Sciences, vol.220, issue.1-2, pp.127-129, 2004.
DOI : 10.1016/j.jns.2004.03.012

L. Benedetti, C. Briani, M. Grandis, T. Vigo, M. Gobbi et al., Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M, Journal of the Peripheral Nervous System, vol.322, issue.2, pp.102-107, 2007.
DOI : 10.1212/01.wnl.0000201193.00382.b3

N. Notermans, Rituximab for polyneuropathy with IgM monoclonal gammopathy, J Neurol Neurosurg Psychiatry, vol.80, issue.9, pp.1036-1039, 2009.